Relatlimab (Opdualag (fixed-dose combination with nivolumab))
Immunotherapy
Description
Relatlimab is a monoclonal antibody immunotherapy agent that targets the LAG-3 (Lymphocyte Activation Gene-3) immune checkpoint receptor. In colorectal cancer, it is being evaluated specifically for microsatellite stable (MSS) tumors, which typically do not respond well to standard PD-1/PD-L1 checkpoint inhibitors. Relatlimab is administered in combination with nivolumab (anti-PD-1) to enhance immune system activation against cancer cells in this challenging patient population.
Mechanism of Action
Relatlimab blocks the LAG-3 receptor on T cells, which normally serves as an immune checkpoint that suppresses T cell activation and proliferation. By inhibiting LAG-3, relatlimab removes this brake on the immune system, allowing T cells to maintain their anti-tumor activity for longer periods and potentially overcome immune suppression in the tumor microenvironment.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Opdualag (fixed-dose combination with nivolumab) |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.